The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
 
Fei Ma
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Huoling Tang
Employment - Bliss Biopharmaceutical
 
Yuhong Zhou
Employment - Bliss Biopharmaceutical
Leadership - Bliss Biopharmaceutical
Stock and Other Ownership Interests - Bliss Biopharmaceutical
Research Funding - Bliss Biopharmaceutical
Patents, Royalties, Other Intellectual Property - Bliss Biopharmaceutical
Travel, Accommodations, Expenses - Bliss Biopharmaceutical
 
Ziping Wei
Employment - Bliss Biopharmaceutical
Leadership - Bliss Biopharmaceutical
Stock and Other Ownership Interests - Bliss Biopharmaceutical
Speakers' Bureau - Bliss Biopharmaceutical
Research Funding - Bliss Biopharmaceutical
Patents, Royalties, Other Intellectual Property - Bliss Biopharmaceutical
Travel, Accommodations, Expenses - Bliss Biopharmaceutical
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - Alkermes; AstraZeneca/Merck; Athenex; GlaxoSmithKline; Olema Pharmaceuticals
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; BeiGene; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Tempest Therapeutics (Inst); Tesaro/GSK (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents